{
  "docId": "019de072-75de-708e-aad9-55788df6c953",
  "docSlug": "5188528054c3088b6a98b04815eb3ce3",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 40 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 40,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "The slide uses a three-column layout to categorize updates. Footer contains detailed methodology and definitions.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-75de-708e-aad9-55788df6c953/5",
  "deckHref": "/decks/019de072-75de-708e-aad9-55788df6c953",
  "deckJsonHref": "/decks/019de072-75de-708e-aad9-55788df6c953.json",
  "deckAnchorHref": "/decks/019de072-75de-708e-aad9-55788df6c953#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.94,
        "x": 0.03,
        "y": 0.85
      },
      "kind": "callout",
      "text": "2022 guidance: high-teens % Total Revenue growth (CER) | mid-to-high twenties % Core EPS growth (CER)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03238900-66c9-46b4-aac6-ae4b0ffcbb73",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.03,
        "y": 0.22
      },
      "kind": "list",
      "text": "Robust growth: Total Revenue $11.4bn (+60%), Core EPS $1.89 (+20%), Reiterating 2022 guidance",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0bed4532-9c5b-4174-94ee-3a6067a52188",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.3,
        "x": 0.67,
        "y": 0.22
      },
      "kind": "list",
      "text": "Science-led innovation: Ultomiris, Saphnelo, Enhertu, Tremelimumab + Imfinzi, Lynparza, Evusheld approvals and reviews",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4240918f-c35f-47c1-8756-a76f1f7310b4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.28,
        "x": 0.35,
        "y": 0.22
      },
      "kind": "list",
      "text": "Broad-based performance: Oncology $3.6bn (+25%), BioPharmaceuticals (CVRM, Respiratory, Vaccines), Rare Disease $1.7bn (+7%)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "470eee0c-d03b-4df9-ad83-c997e8b10b82",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.94,
        "x": 0.03,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Absolute values at actual exchange rates; changes at constant exchange rates (CER)...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3dc60aff-e339-48ff-b057-b5d3a816f118",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.35,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Q1 2022: key updates",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b76f4511-365e-43b3-b9c5-7f081d0c657f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "title",
      "text": "Progress against our strategic objectives",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "82bc9c12-cb4f-4530-a439-b7061320bdf5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "list-presentation",
      "slug": null,
      "matchId": "d2acaec0-a187-4857-8bc2-e57a51029a1b",
      "evidence": "Three-column categorization of strategic pillars",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 5,
      "from": 1,
      "beatId": "19077272-e83b-4b19-a2e1-58ce37d6d4dd",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Attention",
      "beatSlug": "monroes-sequence-attention",
      "evidence": "The opening slides provide an overview of the Q1 2022 results and key updates",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Hook",
      "parentBeatSlug": "hook"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}